Ruconest Injection, Powder, For Solution
Product Images NDC 71274-350

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ruconest (NDC 71274-350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharming Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Packaging label for Ruconest 2100 U injection powder for solution, featuring the proprietary name and generic name c1 esterase inhibitor (recombinant). The label includes storage instructions, inactive ingredients, manufacturer Pharming Americas BV, and distributor Pharming Healthcare Inc. The product is for single patient use, intravenous administration, and contains one vial of 2100 U dose.*

FDA Label Image

Step1 (Image 01)

An illustration showing components of the Ruconest injection for intravenous use. It includes two packets of a powder or tablets, three vial caps or seals, one diluent bottle, two vials labeled Ruconest, and a syringe marked with volume measurements up to 30 mL.*

FDA Label Image

Step2 (Image 02)

An instructional illustration showing a vial of Ruconest (c1 esterase inhibitor recombinant) injection powder for solution with a focus on checking the expiration and lot number at the bottom of the vial label. The vial cap displays the text 'FLIP OFF.' The image emphasizes the importance of verifying vial information before use.*

FDA Label Image

Step3 (Image 03)

An instructional illustration showing hands being washed under running water from a faucet, with soap lather and water visible. The diagram depicts proper hand washing technique, likely related to hygiene instructions.*

FDA Label Image

Reconstitution-step2 (Image 04)

An instructional illustration showing two bottles labeled "DILUENT" and "RUCONEST." Each bottle has an arrow above its cap indicating removal of the cap, demonstrating how to open the bottles for preparation or administration of the ruconest injection powder and diluent solution.*

FDA Label Image

Reconstitution-step4 (Image 05)

An instructional illustration showing the process of attaching or inserting a component onto the top of a vial labeled 'DILUENT.' An arrow indicates the downward motion of the component towards the vial cap, suggesting preparation steps for reconstitution or dilution.*

FDA Label Image

Reconstitution-step5 (Image 06)

An illustration showing a vial labeled RUCONEST with a stopper above it and a downward arrow indicating the stopper being placed onto the vial. This likely represents how to seal or close the RUCONEST injection vial containing c1 esterase inhibitor recombinant 2100 U/1 dosage form by Pharming Healthcare Inc.*

FDA Label Image

Reconstitution-step7 (Image 07)

An instructional illustration showing a vial labeled 'DILUENT' connected upside down to a syringe. The syringe is marked with volume graduations up to 25 mL, and an arrow indicates downward movement, suggesting the diluent is being drawn into the syringe for reconstitution or dilution of a medication.*

FDA Label Image

Reconstitution-step8 (Image 08)

An instructional illustration showing a syringe drawing liquid from a vial labeled Ruconest. The syringe is marked with measurement increments up to 30 mL, and an arrow indicates the direction of withdrawing the solution from the vial.*

FDA Label Image

Reconstitution-step9 (Image 09)

Illustration showing a hand holding a vial labeled Ruconest while a syringe is inserted into the vial stopper. The image includes an arrow indicating the vial is being rotated during the solution preparation process for intravenous injection.*

FDA Label Image

Reconstitution-step10 (Image 10)

An instructional illustration showing a hand holding a vial labeled 'RUCONEST' while a syringe is inserted into the vial stopper, depicting preparation of an intravenous injection of Ruconest (c1 esterase inhibitor recombinant) powder for solution.*

FDA Label Image

Reconstitution-step11a (Image 11)

An instructional illustration showing a Ruconest vial attached upside down to a syringe filled with liquid, with an arrow indicating downward pressure on the syringe plunger to draw or dispense the solution. It demonstrates proper assembly for preparing Ruconest injection, powder for solution.*

FDA Label Image

Reconstitution-step11b (Image 12)

An instructional diagram showing a syringe connected to a vial labeled Ruconest. The illustration features an arrow indicating to pull the syringe plunger upwards and a rotational arrow on the syringe barrel, demonstrating the extraction process of the solution from the vial.*

FDA Label Image

Self-step1 (Image 13)

Black and white instructional illustration showing medical supplies including a roll of tape, a sterile wipe packet, a stack of alcohol prep pads, a syringe marked with 5 to 20 ml gradations, tubing for intravenous use, and a narrow strip of adhesive tape.*

FDA Label Image

Self-step3 (Image 14)

An instructional line drawing showing two hands holding a syringe connected to a flexible tube with a luer lock connector at the end. The illustration likely demonstrates preparation or use of an injection device.*

FDA Label Image

Self-step4 (Image 15)

An instructional illustration showing a person's forearm with an upward arrow indicating the action of pressing or rubbing a patch or pad onto the skin above the wrist. The arm is secured with a band near the elbow.*

FDA Label Image

Self-step5a (Image 16)

An instructional illustration showing a syringe connected to an intravenous catheter placed in the vein of a forearm. The image depicts the setup for intravenous injection, indicating the insertion site and fluid flow direction into the vein.*

FDA Label Image

Self-step5b (Image 17)

A black and white instructional illustration showing a hand holding a syringe with the plunger partially depressed. The syringe is marked with measurement gradations in milliliters, and a downward arrow indicates the direction of liquid flow or injection.*

FDA Label Image

Self-step5c (Image 18)

An instructional illustration showing an arm with a butterfly needle inserted for intravenous injection. A clock face above indicates a 5-minute duration, likely representing the recommended infusion time for the injection.*

FDA Label Image

Self-step6 (Image 19)

An instructional illustration showing a hand cleaning the inner forearm with a swab, indicating site preparation for intravenous injection. A vial, tubing, and a biohazard sharps disposal container are also depicted, suggesting preparation and safe disposal of injection materials.*

FDA Label Image

Label (Label)

Label for Ruconest 2100 U injection powder for solution, a recombinant c1 esterase inhibitor. The label shows it is for intravenous use only and single patient use. Manufactured by Pharming Americas B.V., Netherlands, and distributed by Pharming Healthcare Inc., New Jersey. Includes NDC 71274-350-01 and a barcode.*

FDA Label Image

Pharming (Pharming)

FDA Label Image

Pharming (Pharming2)

Ruconest 2100 U/1 Injection, Powder, for Solution label from Pharming Healthcare Inc. The label includes branding with Pharming's logo, product name Ruconest, generic name c1 esterase inhibitor recombinant, and dosage strength 2100 U/1. The packaging is primarily blue and white with clear product identification for intravenous use.*

FDA Label Image

Figure1 (Ruconest 1)

A line graph comparing the proportion of patients with relief over time (in hours) between Ruconest and placebo treatments. The x-axis represents time to event in hours, and the y-axis shows the proportion of patients with relief. The graph includes censor flags for both treatment groups, with Ruconest shown in blue solid lines and placebo in red dashed lines.*

FDA Label Image

Figure-two (Ruconest 2)

A line graph showing treatment effects over time in hours for Ruconest injections at doses of 100 IU/kg and 50 IU/kg compared to a placebo. The vertical axis represents a quantitative measurement with error bars illustrating variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.